NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical...